FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969428984> ?p ?o ?g. }

• W2969428984 abstract "Irritable bowel syndrome with diarrhoea (IBS-D) affects up to 4% of the general population. Symptoms include frequent, loose, or watery stools with associated urgency, resulting in marked reduction of quality of life and loss of work productivity. Ondansetron, a 5HT3 receptor antagonist, has had an excellent safety record for over 20 years as an antiemetic, yet is not widely used in the treatment of IBS-D. It has, however, been shown to slow colonic transit and in a small randomised, placebo-controlled, cross-over pilot study, benefited patients with IBS-D. This trial is a phase III, parallel group, randomised, double-blind, multi-centre, placebo-controlled trial, with embedded mechanistic studies. Participants (n = 400) meeting Rome IV criteria for IBS-D will be recruited from outpatient and primary care clinics and by social media to receive either ondansetron (dose titrated up to 24 mg daily) or placebo for 12 weeks. Throughout the trial, participants will record their worst abdominal pain, worst urgency, stool frequency, and stool consistency on a daily basis. The primary endpoint is the proportion of “responders” in each group, using Food and Drug Administration (FDA) recommendations. Secondary endpoints include pain intensity, stool consistency, frequency, and urgency. Mood and quality of life will also be assessed. Mechanistic assessments will include whole gut transit, faecal tryptase and faecal bile acid concentrations at baseline and between weeks 8 and 11. A subgroup of participants will also undergo assessment of sensitivity (n = 80) using the barostat, and/or high-resolution colonic manometry (n = 40) to assess motor patterns in the left colon and the impact of ondansetron. The TRITON trial aims to assess the effect of ondansetron across multiple centres. By defining ondansetron’s mechanisms of action we hope to better identify patients with IBS-D who are likely to respond. ISRCTN, ISRCTN17508514 , Registered on 2 October 2017." @default.
• W2969428984 created "2019-08-29" @default.
• W2969428984 creator A5003449281 @default.
• W2969428984 creator A5006399379 @default.
• W2969428984 creator A5007597546 @default.
• W2969428984 creator A5009868105 @default.
• W2969428984 creator A5010953161 @default.
• W2969428984 creator A5019695904 @default.
• W2969428984 creator A5020188220 @default.
• W2969428984 creator A5025591995 @default.
• W2969428984 creator A5026037485 @default.
• W2969428984 creator A5028232421 @default.
• W2969428984 creator A5037195356 @default.
• W2969428984 creator A5039104549 @default.
• W2969428984 creator A5044392782 @default.
• W2969428984 creator A5047361542 @default.
• W2969428984 creator A5048856615 @default.
• W2969428984 creator A5052875343 @default.
• W2969428984 creator A5053480723 @default.
• W2969428984 creator A5054250912 @default.
• W2969428984 creator A5056320849 @default.
• W2969428984 creator A5062682250 @default.
• W2969428984 creator A5070556531 @default.
• W2969428984 creator A5072794803 @default.
• W2969428984 creator A5081916513 @default.
• W2969428984 creator A5085383220 @default.
• W2969428984 creator A5091245648 @default.
• W2969428984 date "2019-08-20" @default.
• W2969428984 modified "2023-10-14" @default.
• W2969428984 title "Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial" @default.
• W2969428984 cites W1567581279 @default.
• W2969428984 cites W1580849471 @default.
• W2969428984 cites W1845447069 @default.
• W2969428984 cites W1889441578 @default.
• W2969428984 cites W1982298970 @default.
• W2969428984 cites W1998457950 @default.
• W2969428984 cites W2007655479 @default.
• W2969428984 cites W2017242867 @default.
• W2969428984 cites W2035844345 @default.
• W2969428984 cites W2044106516 @default.
• W2969428984 cites W2046549547 @default.
• W2969428984 cites W2048245148 @default.
• W2969428984 cites W2059925861 @default.
• W2969428984 cites W2065530845 @default.
• W2969428984 cites W2074762600 @default.
• W2969428984 cites W2076995479 @default.
• W2969428984 cites W2095075068 @default.
• W2969428984 cites W2099964125 @default.
• W2969428984 cites W2108696783 @default.
• W2969428984 cites W2116314888 @default.
• W2969428984 cites W2121087428 @default.
• W2969428984 cites W2121260720 @default.
• W2969428984 cites W2129997920 @default.
• W2969428984 cites W2132122176 @default.
• W2969428984 cites W2137645401 @default.
• W2969428984 cites W2140619466 @default.
• W2969428984 cites W2146589073 @default.
• W2969428984 cites W2158025174 @default.
• W2969428984 cites W2166281097 @default.
• W2969428984 cites W2168877909 @default.
• W2969428984 cites W2333050500 @default.
• W2969428984 cites W2601888614 @default.
• W2969428984 cites W2606537879 @default.
• W2969428984 cites W4236805817 @default.
• W2969428984 doi "https://doi.org/10.1186/s13063-019-3562-6" @default.
• W2969428984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6700805" @default.
• W2969428984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31429811" @default.
• W2969428984 hasPublicationYear "2019" @default.
• W2969428984 type Work @default.
• W2969428984 sameAs 2969428984 @default.
• W2969428984 citedByCount "11" @default.
• W2969428984 countsByYear W29694289842020 @default.
• W2969428984 countsByYear W29694289842021 @default.
• W2969428984 countsByYear W29694289842022 @default.
• W2969428984 countsByYear W29694289842023 @default.
• W2969428984 crossrefType "journal-article" @default.
• W2969428984 hasAuthorship W2969428984A5003449281 @default.
• W2969428984 hasAuthorship W2969428984A5006399379 @default.
• W2969428984 hasAuthorship W2969428984A5007597546 @default.
• W2969428984 hasAuthorship W2969428984A5009868105 @default.
• W2969428984 hasAuthorship W2969428984A5010953161 @default.
• W2969428984 hasAuthorship W2969428984A5019695904 @default.
• W2969428984 hasAuthorship W2969428984A5020188220 @default.
• W2969428984 hasAuthorship W2969428984A5025591995 @default.
• W2969428984 hasAuthorship W2969428984A5026037485 @default.
• W2969428984 hasAuthorship W2969428984A5028232421 @default.
• W2969428984 hasAuthorship W2969428984A5037195356 @default.
• W2969428984 hasAuthorship W2969428984A5039104549 @default.
• W2969428984 hasAuthorship W2969428984A5044392782 @default.
• W2969428984 hasAuthorship W2969428984A5047361542 @default.
• W2969428984 hasAuthorship W2969428984A5048856615 @default.
• W2969428984 hasAuthorship W2969428984A5052875343 @default.
• W2969428984 hasAuthorship W2969428984A5053480723 @default.
• W2969428984 hasAuthorship W2969428984A5054250912 @default.
• W2969428984 hasAuthorship W2969428984A5056320849 @default.
• W2969428984 hasAuthorship W2969428984A5062682250 @default.
• W2969428984 hasAuthorship W2969428984A5070556531 @default.
• W2969428984 hasAuthorship W2969428984A5072794803 @default.
• W2969428984 hasAuthorship W2969428984A5081916513 @default.
• W2969428984 hasAuthorship W2969428984A5085383220 @default.

• next